50
edits
Changes
Jump to navigation
Jump to search
Line 1:
Line 1: − <span style="color:#0070C0">(''General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])''</span> − − Put your text here<span style="color:#0070C0"> (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics) </span>+ Line 9:
Line 7: − Put your text here+ − Put your text here + Line 21:
Line 19: − Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>+ − Put your text here+ − Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>+ Line 48:
Line 46: − Put your text here <span style="color:#0070C0">(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'') </span>+ − Put your text here+ + + − Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>+ Line 62:
Line 62: − + − + − + − + − Put your text here and fill in the table+ Line 83:
Line 83: − + − EXAMPLE 30% (add reference)+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + − + − − The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). − Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>+ Line 105:
Line 140: − + − + − 7+ − + − + − + − chr7:1- 159,335,973 [hg38]+ − + − − chr7 − − − − − − Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference). − + − + − 8+ − + − + − + − chr8:1-145,138,636 [hg38]+ − + − − chr8 − − − − − − Common recurrent secondary finding for t(8;21) (add reference). − Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>+ Line 151:
Line 170: − + − + − Co-deletion of 1p and 18q+ − + − + − − − − See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). − Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>+ Line 173:
Line 188: − + − + − EXAMPLE:+ − + − EGFR; Exon 20 mutations+ − + − EXAMPLE: BRAF; Activating mutations − − − − EXAMPLE: 30% (add Reference) − − − |EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference). − <br /> Line 196:
Line 202: − Put your text here+ − Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>+ − + − + − + + + + + + + + + − + − + − + − + − + − + − Put your text here+ − Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>+ − Put your text here+ − Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page <span style="color:#0070C0">(''Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "<nowiki>http://www</nowiki>." portion.'')</span>+
BRST5:Inflammatory Myofibroblastic Tumour (view source)
Revision as of 09:49, 7 December 2023
, 09:49, 7 December 2023no edit summary
==Primary Author(s)*==
==Primary Author(s)*==
Yajuan Liu, PhD, University of Washington
__TOC__
__TOC__
==Cancer Category / Type==
==Cancer Category / Type==
Mesenchymal tumours of the breast
==Cancer Sub-Classification / Subtype==
==Cancer Sub-Classification / Subtype==
Fibroblastic and myofibroblastic tumors
==Definition / Description of Disease==
==Definition / Description of Disease==
==Synonyms / Terminology==
==Synonyms / Terminology==
Related terminology: inflammatory pseudotumour (historical, not recommended), inflammatory fibrosarcoma (historical, not recommended); plasma cell granuloma (historical, not recommended)
==Epidemiology / Prevalence==
==Epidemiology / Prevalence==
Breast IMTs most often affect young to middle-aged females, although the age range is broad.<ref name=":0">{{Cite journal|last=Coffin|first=C. M.|last2=Watterson|first2=J.|last3=Priest|first3=J. R.|last4=Dehner|first4=L. P.|date=1995-08|title=Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases|url=https://pubmed.ncbi.nlm.nih.gov/7611533|journal=The American Journal of Surgical Pathology|volume=19|issue=8|pages=859–872|doi=10.1097/00000478-199508000-00001|issn=0147-5185|pmid=7611533}}</ref><ref>{{Cite journal|last=Makhlouf|first=Hala R.|last2=Sobin|first2=Leslie H.|date=2002-03|title=Inflammatory myofibroblastic tumors (inflammatory pseudotumors) of the gastrointestinal tract: how closely are they related to inflammatory fibroid polyps?|url=https://pubmed.ncbi.nlm.nih.gov/11979371|journal=Human Pathology|volume=33|issue=3|pages=307–315|doi=10.1053/hupa.2002.32213|issn=0046-8177|pmid=11979371}}</ref>
==Clinical Features==
==Clinical Features==
Breast IMT usually presents as a painless, circumscribed mass.
{| class="wikitable"
{| class="wikitable"
|'''Signs and Symptoms'''
|'''Signs and Symptoms'''
==Sites of Involvement==
==Sites of Involvement==
Breast IMT is rare and fewer than 25 reported cases.<ref>{{Cite journal|last=Khanafshar|first=Elham|last2=Phillipson|first2=Julia|last3=Schammel|first3=David P.|last4=Minobe|first4=Lorraine|last5=Cymerman|first5=Judith|last6=Weidner|first6=Noel|date=2005-06|title=Inflammatory myofibroblastic tumor of the breast|url=https://pubmed.ncbi.nlm.nih.gov/15944952|journal=Annals of Diagnostic Pathology|volume=9|issue=3|pages=123–129|doi=10.1016/j.anndiagpath.2005.02.001|issn=1092-9134|pmid=15944952}}</ref><ref>{{Cite journal|last=Haj|first=Mahmoud|last2=Weiss|first2=Michael|last3=Loberant|first3=Norman|last4=Cohen|first4=Isaac|date=2003|title=Inflammatory pseudotumor of the breast: case report and literature review|url=https://pubmed.ncbi.nlm.nih.gov/12968967|journal=The Breast Journal|volume=9|issue=5|pages=423–425|doi=10.1046/j.1524-4741.2003.09516.x|issn=1075-122X|pmid=12968967}}</ref><ref>{{Cite journal|last=Zhao|first=Hua-Dong|last2=Wu|first2=Tao|last3=Wang|first3=Jun-Qing|last4=Zhang|first4=Wen-Dong|last5=He|first5=Xian-Li|last6=Bao|first6=Guo-Qiang|last7=Li|first7=Yi|last8=Gong|first8=Li|last9=Wang|first9=Qing|date=2013-01|title=Primary inflammatory myofibroblastic tumor of the breast with rapid recurrence and metastasis: A case report|url=https://pubmed.ncbi.nlm.nih.gov/23255901|journal=Oncology Letters|volume=5|issue=1|pages=97–100|doi=10.3892/ol.2012.948|issn=1792-1074|pmc=3525499|pmid=23255901}}</ref><ref>{{Cite journal|last=Kovács|first=Anikó|last2=Máthé|first2=Gyöngyvér|last3=Mattsson|first3=Jan|last4=Stenman|first4=Göran|last5=Kindblom|first5=Lars-Gunnar|date=2015|title=ALK-Positive Inflammatory Myofibroblastic Tumor of the Nipple During Pregnancy-An Unusual Presentation of a Rare Disease|url=https://pubmed.ncbi.nlm.nih.gov/25772857|journal=The Breast Journal|volume=21|issue=3|pages=297–302|doi=10.1111/tbj.12404|issn=1524-4741|pmid=25772857}}</ref> IMT shows a wide anatomical distribution, most frequently arising in the respiratory tract, abdominal cavity, and retroperitoneum, followed by the lung, mediastinum, head and neck, gastrointestinal tract, and genitourinary tract (including the bladder and uterus).<ref name=":0" /><ref name=":1">{{Cite journal|last=Gleason|first=B. C.|last2=Hornick|first2=J. L.|date=2008-04|title=Inflammatory myofibroblastic tumours: where are we now?|url=https://pubmed.ncbi.nlm.nih.gov/17938159|journal=Journal of Clinical Pathology|volume=61|issue=4|pages=428–437|doi=10.1136/jcp.2007.049387|issn=1472-4146|pmid=17938159}}</ref><ref>{{Cite journal|last=Karnak|first=I.|last2=Senocak|first2=M. E.|last3=Ciftci|first3=A. O.|last4=Cağlar|first4=M.|last5=Bingöl-Koloğlu|first5=M.|last6=Tanyel|first6=F. C.|last7=Büyükpamukçu|first7=N.|date=2001-06|title=Inflammatory myofibroblastic tumor in children: diagnosis and treatment|url=https://pubmed.ncbi.nlm.nih.gov/11381424|journal=Journal of Pediatric Surgery|volume=36|issue=6|pages=908–912|doi=10.1053/jpsu.2001.23970|issn=0022-3468|pmid=11381424}}</ref><ref>{{Cite journal|last=Tsuzuki|first=Toyonori|last2=Magi-Galluzzi|first2=Cristina|last3=Epstein|first3=Jonathan I.|date=2004-12|title=ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder|url=https://pubmed.ncbi.nlm.nih.gov/15577680|journal=The American Journal of Surgical Pathology|volume=28|issue=12|pages=1609–1614|doi=10.1097/00000478-200412000-00009|issn=0147-5185|pmid=15577680}}</ref> Unusual locations include somatic soft tissues, pancreas, liver, and CNS.<ref name=":0" /><ref name=":1" /><ref>{{Cite journal|last=Ramachandra|first=S.|last2=Hollowood|first2=K.|last3=Bisceglia|first3=M.|last4=Fletcher|first4=C. D.|date=1995-10|title=Inflammatory pseudotumour of soft tissues: a clinicopathological and immunohistochemical analysis of 18 cases|url=https://pubmed.ncbi.nlm.nih.gov/8847061|journal=Histopathology|volume=27|issue=4|pages=313–323|doi=10.1111/j.1365-2559.1995.tb01521.x|issn=0309-0167|pmid=8847061}}</ref>
==Morphologic Features==
==Morphologic Features==
Most tumors are < 5 cm in size, with white to grey and sometimes yellow cut surfaces.
Loose fascicles of uniform, plump spindle cells with vesicular chromatin, small nucleoli, and pale eosinophilic to amphophilic cytoplasm are typically observed. <ref name=":0" /> The stroma may be myxoid or collagenous, usually containing an inflammatory infiltrate dominated by lymphocytes and plasma cells, with fewer eosinophils and neutrophils. Some tumours exhibit a compact, fascicular architecture with minimal stroma. A subset of tumour cells may resemble ganglion cells. Mitotic activity is low and necrosis is usually absent.
==Immunophenotype==
==Immunophenotype==
Essential and desirable diagnostic criteria include loose fascicles of plump spindle cells without substantial atypia or pleomorphism; inflammatory infiltrate of lymphocytes and plasma cells; consistent SMA expression; frequent ALK expression.
{| class="wikitable sortable"
{| class="wikitable sortable"
!Finding!!Marker
!Finding!!Marker
|-
|-
|Positive (universal)||EXAMPLE CD1
|Positive (universal)||SMA
|-
|-
|Positive (subset)||EXAMPLE CD2
|Positive (subset)||desmin, ALK (~60%),<ref name=":2">{{Cite journal|last=Cook|first=J. R.|last2=Dehner|first2=L. P.|last3=Collins|first3=M. H.|last4=Ma|first4=Z.|last5=Morris|first5=S. W.|last6=Coffin|first6=C. M.|last7=Hill|first7=D. A.|date=2001-11|title=Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study|url=https://pubmed.ncbi.nlm.nih.gov/11684952|journal=The American Journal of Surgical Pathology|volume=25|issue=11|pages=1364–1371|doi=10.1097/00000478-200111000-00003|issn=0147-5185|pmid=11684952}}</ref><ref name=":3">{{Cite journal|last=Pickett|first=Justine L.|last2=Chou|first2=Angela|last3=Andrici|first3=Juliana A.|last4=Clarkson|first4=Adele|last5=Sioson|first5=Loretta|last6=Sheen|first6=Amy|last7=Reagh|first7=Jessica|last8=Najdawi|first8=Fedaa|last9=Kim|first9=Yoomee|date=2017-10|title=Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required|url=https://pubmed.ncbi.nlm.nih.gov/28731868|journal=The American Journal of Surgical Pathology|volume=41|issue=10|pages=1433–1442|doi=10.1097/PAS.0000000000000909|issn=1532-0979|pmc=5598906|pmid=28731868}}</ref> ROS1 (~5%)<ref name=":4">{{Cite journal|last=Hornick|first=Jason L.|last2=Sholl|first2=Lynette M.|last3=Dal Cin|first3=Paola|last4=Childress|first4=Merrida A.|last5=Lovly|first5=Christine M.|date=2015-05|title=Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors|url=https://pubmed.ncbi.nlm.nih.gov/25612511|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=28|issue=5|pages=732–739|doi=10.1038/modpathol.2014.165|issn=1530-0285|pmc=5874150|pmid=25612511}}</ref> <ref name=":5">{{Cite journal|last=Antonescu|first=Cristina R.|last2=Suurmeijer|first2=Albert J. H.|last3=Zhang|first3=Lei|last4=Sung|first4=Yun-Shao|last5=Jungbluth|first5=Achim A.|last6=Travis|first6=William D.|last7=Al-Ahmadie|first7=Hikmat|last8=Fletcher|first8=Christopher D. M.|last9=Alaggio|first9=Rita|date=2015-07|title=Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement|url=https://pubmed.ncbi.nlm.nih.gov/25723109|journal=The American Journal of Surgical Pathology|volume=39|issue=7|pages=957–967|doi=10.1097/PAS.0000000000000404|issn=1532-0979|pmc=4465992|pmid=25723109}}</ref>
|-
|-
|Negative (universal)||EXAMPLE CD3
|Negative (universal)||keratin
|-
|-
|Negative (subset)||EXAMPLE CD4
|Negative (subset)||CD34, S100, SOX10, and EMA
|}
|}
==Chromosomal Rearrangements (Gene Fusions)==
==Chromosomal Rearrangements (Gene Fusions)==
Confirmation of ALK or other gene rearrangements supports the diagnosis. However, molecular confirmation is not required if ALK immunohistochemistry is definitively positive.<ref name=":6">{{Cite journal|last=Coffin|first=C. M.|last2=Patel|first2=A.|last3=Perkins|first3=S.|last4=Elenitoba-Johnson|first4=K. S.|last5=Perlman|first5=E.|last6=Griffin|first6=C. A.|date=2001-06|title=ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor|url=https://pubmed.ncbi.nlm.nih.gov/11406658|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=14|issue=6|pages=569–576|doi=10.1038/modpathol.3880352|issn=0893-3952|pmid=11406658}}</ref> Of note, exceptional situations such as inversion of ALK on the same chromosome arm may lead to a false-negative FISH result. <ref>{{Cite journal|last=Haimes|first=Josh D.|last2=Stewart|first2=Colin J. R.|last3=Kudlow|first3=Brian A.|last4=Culver|first4=Brady P.|last5=Meng|first5=Bo|last6=Koay|first6=Eleanor|last7=Whitehouse|first7=Ann|last8=Cope|first8=Nichola|last9=Lee|first9=Jen-Chieh|date=2017-06|title=Uterine Inflammatory Myofibroblastic Tumors Frequently Harbor ALK Fusions With IGFBP5 and THBS1|url=https://pubmed.ncbi.nlm.nih.gov/28490045|journal=The American Journal of Surgical Pathology|volume=41|issue=6|pages=773–780|doi=10.1097/PAS.0000000000000801|issn=1532-0979|pmid=28490045}}</ref>, and other molecular testing such as RNA-Seq can be used to detect ALK fusions efficiently. In ALK-negative cases, immunohistochemistry for ROS1 and/or molecular tests for non-ALK gene fusions (e.g. NTRK3) may be useful.<ref name=":7">{{Cite journal|last=Yamamoto|first=Hidetaka|last2=Yoshida|first2=Akihiko|last3=Taguchi|first3=Kenichi|last4=Kohashi|first4=Kenichi|last5=Hatanaka|first5=Yui|last6=Yamashita|first6=Atsushi|last7=Mori|first7=Daisuke|last8=Oda|first8=Yoshinao|date=2016-07|title=ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours|url=https://pubmed.ncbi.nlm.nih.gov/26647767|journal=Histopathology|volume=69|issue=1|pages=72–83|doi=10.1111/his.12910|issn=1365-2559|pmid=26647767}}</ref><ref name=":8">{{Cite journal|last=Lovly|first=Christine M.|last2=Gupta|first2=Abha|last3=Lipson|first3=Doron|last4=Otto|first4=Geoff|last5=Brennan|first5=Tina|last6=Chung|first6=Catherine T.|last7=Borinstein|first7=Scott C.|last8=Ross|first8=Jeffrey S.|last9=Stephens|first9=Philip J.|date=2014-08|title=Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions|url=https://pubmed.ncbi.nlm.nih.gov/24875859|journal=Cancer Discovery|volume=4|issue=8|pages=889–895|doi=10.1158/2159-8290.CD-14-0377|issn=2159-8290|pmc=4125481|pmid=24875859}}</ref><ref name=":9">{{Cite journal|last=Alassiri|first=Ali H.|last2=Ali|first2=Rola H.|last3=Shen|first3=Yaoqing|last4=Lum|first4=Amy|last5=Strahlendorf|first5=Caron|last6=Deyell|first6=Rebecca|last7=Rassekh|first7=Rod|last8=Sorensen|first8=Poul H.|last9=Laskin|first9=Janessa|date=2016-08|title=ETV6-NTRK3 Is Expressed in a Subset of ALK-Negative Inflammatory Myofibroblastic Tumors|url=https://pubmed.ncbi.nlm.nih.gov/27259007|journal=The American Journal of Surgical Pathology|volume=40|issue=8|pages=1051–1061|doi=10.1097/PAS.0000000000000677|issn=1532-0979|pmid=27259007}}</ref><ref name=":5" />
{| class="wikitable sortable"
{| class="wikitable sortable"
!Notes
!Notes
|-
|-
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
|t(2;var)(p23;var)||5'var::3'''ALK''
(various 5’partner genes include ''TPM3'', ''TPM4'', ''CLTC'', ''CARS'', ''ATIC'', ''SEC31L1'', ''PPFIBP1'', ''DCTN1'', ''EML4'', ''PRKAR1A'', ''LMNA'', ''TFG'', ''FN1'', ''HNRNPA1'', etc)
|der(var)||50-60%<ref name=":10">{{Cite journal|last=Bridge|first=J. A.|last2=Kanamori|first2=M.|last3=Ma|first3=Z.|last4=Pickering|first4=D.|last5=Hill|first5=D. A.|last6=Lydiatt|first6=W.|last7=Lui|first7=M. Y.|last8=Colleoni|first8=G. W.|last9=Antonescu|first9=C. R.|date=2001-08|title=Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor|url=https://pubmed.ncbi.nlm.nih.gov/11485898|journal=The American Journal of Pathology|volume=159|issue=2|pages=411–415|doi=10.1016/S0002-9440(10)61711-7|issn=0002-9440|pmc=1850566|pmid=11485898}}</ref><ref>{{Cite journal|last=Chen|first=Sung-Ting|last2=Lee|first2=Jen-Chieh|date=2008-12|title=An inflammatory myofibroblastic tumor in liver with ALK and RANBP2 gene rearrangement: combination of distinct morphologic, immunohistochemical, and genetic features|url=https://pubmed.ncbi.nlm.nih.gov/18701132|journal=Human Pathology|volume=39|issue=12|pages=1854–1858|doi=10.1016/j.humpath.2008.04.016|issn=1532-8392|pmid=18701132}}</ref><ref>{{Cite journal|last=Debelenko|first=Larisa V.|last2=Arthur|first2=Diane C.|last3=Pack|first3=Svetlana D.|last4=Helman|first4=Lee J.|last5=Schrump|first5=David S.|last6=Tsokos|first6=Maria|date=2003-09|title=Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor|url=https://pubmed.ncbi.nlm.nih.gov/13679433|journal=Laboratory Investigation; a Journal of Technical Methods and Pathology|volume=83|issue=9|pages=1255–1265|doi=10.1097/01.lab.0000088856.49388.ea|issn=0023-6837|pmid=13679433}}</ref><ref>{{Cite journal|last=Griffin|first=C. A.|last2=Hawkins|first2=A. L.|last3=Dvorak|first3=C.|last4=Henkle|first4=C.|last5=Ellingham|first5=T.|last6=Perlman|first6=E. J.|date=1999-06-15|title=Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors|url=https://pubmed.ncbi.nlm.nih.gov/10383129|journal=Cancer Research|volume=59|issue=12|pages=2776–2780|issn=0008-5472|pmid=10383129}}</ref><ref>{{Cite journal|last=Lawrence|first=B.|last2=Perez-Atayde|first2=A.|last3=Hibbard|first3=M. K.|last4=Rubin|first4=B. P.|last5=Dal Cin|first5=P.|last6=Pinkus|first6=J. L.|last7=Pinkus|first7=G. S.|last8=Xiao|first8=S.|last9=Yi|first9=E. S.|date=2000-08|title=TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors|url=https://pubmed.ncbi.nlm.nih.gov/10934142|journal=The American Journal of Pathology|volume=157|issue=2|pages=377–384|doi=10.1016/S0002-9440(10)64550-6|issn=0002-9440|pmc=1850130|pmid=10934142}}</ref><ref>{{Cite journal|last=Takeuchi|first=Kengo|last2=Soda|first2=Manabu|last3=Togashi|first3=Yuki|last4=Sugawara|first4=Emiko|last5=Hatano|first5=Satoko|last6=Asaka|first6=Reimi|last7=Okumura|first7=Sakae|last8=Nakagawa|first8=Ken|last9=Mano|first9=Hiroyuki|date=2011-05-15|title=Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification|url=https://pubmed.ncbi.nlm.nih.gov/21430068|journal=Clinical Cancer Research: An Official Journal of the American Association for Cancer Research|volume=17|issue=10|pages=3341–3348|doi=10.1158/1078-0432.CCR-11-0063|issn=1557-3265|pmid=21430068}}</ref><ref>{{Cite journal|last=Yamamoto|first=Hidetaka|last2=Kohashi|first2=Kenichi|last3=Oda|first3=Yoshinao|last4=Tamiya|first4=Sadafumi|last5=Takahashi|first5=Yukiko|last6=Kinoshita|first6=Yoshiaki|last7=Ishizawa|first7=Shin|last8=Kubota|first8=Masayuki|last9=Tsuneyoshi|first9=Masazumi|date=2006-10|title=Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene|url=https://pubmed.ncbi.nlm.nih.gov/16984614|journal=Pathology International|volume=56|issue=10|pages=584–590|doi=10.1111/j.1440-1827.2006.02012.x|issn=1320-5463|pmid=16984614}}</ref><ref>{{Cite journal|last=Inamura|first=Kentaro|last2=Kobayashi|first2=Maki|last3=Nagano|first3=Hiroko|last4=Sugiura|first4=Yoshiya|last5=Ogawa|first5=Masahiro|last6=Masuda|first6=Hitoshi|last7=Yonese|first7=Junji|last8=Ishikawa|first8=Yuichi|date=2017-11|title=A novel fusion of HNRNPA1-ALK in inflammatory myofibroblastic tumor of urinary bladder|url=https://pubmed.ncbi.nlm.nih.gov/28504207|journal=Human Pathology|volume=69|pages=96–100|doi=10.1016/j.humpath.2017.04.022|issn=1532-8392|pmid=28504207}}</ref><ref name=":8" />
|Yes
|Yes
|Yes (ALK-negative IMTs may have a higher likelihood of metastasis)
|Yes
|IMT with ALK genomic rearrangement features activation and overexpression of the ALK C-terminal kinase region, which is restricted to the neoplastic myofibroblastic component <ref name=":10" /><ref name=":6" /><ref name=":2" />
|-
|t(3;6)(q12.2;q22.1), t(6;17)(q22.1;p13.3)
|''TFG''::''ROS1'', ''YWHAE''::''ROS1''
|der(var)
|5-10%<ref name=":8" /><ref name=":4" /><ref name=":9" /><ref name=":5" /><ref name=":7" />
|Yes
|No
|Yes
|
|-
|t(12;15)(p13.2;q25.3)
|''ETV6''::''NTRK3''
|der(15)
|>5%<ref name=":8" /><ref name=":5" />
|Yes
|No
|Yes
|Therapy options for NTRK fusions include Larotrectinib and Entrectinib (clinically approved)
|-
|t(5;12)(q32;q13.3)
|NAB2::PDGFRB
|der(5)
|>1%<ref name=":8" />
|Unknown
|No
|Yes
|
|-
|rea(10q11.21)
|rea(RET)
|der(10)
|>1%<ref name=":5" />
|Unknown
|No
|No
|Yes
|Yes
|EXAMPLE
|Detected by FISH break-apart probe
|}
|}
==Individual Region Genomic Gain / Loss / LOH==
==Individual Region Genomic Gain / Loss / LOH==
NA
{| class="wikitable sortable"
{| class="wikitable sortable"
!Notes
!Notes
|-
|-
|EXAMPLE
|NA
|NA
|
|EXAMPLE Loss
|
|EXAMPLE
|
|
|
|EXAMPLE
|
|Yes
|Yes
|No
|EXAMPLE
|-
|-
|EXAMPLE
|NA
|NA
|
|EXAMPLE Gain
|
|EXAMPLE
|
|
|
|EXAMPLE
|.
|No
|No
|No
|EXAMPLE
|}
|}
==Characteristic Chromosomal Patterns==
==Characteristic Chromosomal Patterns==
NA
{| class="wikitable sortable"
{| class="wikitable sortable"
!Notes
!Notes
|-
|-
|EXAMPLE
|NA
|
|
|Yes
|
|No
|
|No
|EXAMPLE:
|}
|}
==Gene Mutations (SNV / INDEL)==
==Gene Mutations (SNV / INDEL)==
NA
{| class="wikitable sortable"
{| class="wikitable sortable"
!Notes
!Notes
|-
|-
|EXAMPLE: TP53; Variable LOF mutations
|NA
|
|
|
|
|
|EXAMPLE: TSG
|EXAMPLE: 20% (COSMIC)
|EXAMPLE: IDH1 R123H
|EXAMPLE: EGFR amplification
|
|
|
|
|
|
|}
|}
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
==Epigenomic Alterations==
==Epigenomic Alterations==
NA
==Genes and Main Pathways Involved==
==Genes and Main Pathways Involved==
IMTs are genetically heterogeneous. About two thirds of inflammatory myofibroblastic tumours harbour receptor tyrosine kinase gene rearrangements, most often involving the ''ALK'' locus at 2p23, with diverse fusion partners. <ref>{{Cite journal|last=Mariño-Enríquez|first=Adrian|last2=Dal Cin|first2=Paola|date=2013-11|title=ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages|url=https://pubmed.ncbi.nlm.nih.gov/24091028|journal=Cancer Genetics|volume=206|issue=11|pages=357–373|doi=10.1016/j.cancergen.2013.07.001|issn=2210-7762|pmid=24091028}}</ref> Approximately 5% of inflammatory myofibroblastic tumours harbour ''ROS1'' gene fusions; other rare gene fusions involve ''NTRK3'', ''PDGFRB'', and ''RET.'' <ref name=":8" /><ref name=":5" /><ref name=":7" /><ref name=":9" /><ref name=":3" />
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|-
|EXAMPLE: BRAF and MAP2K1; Activating mutations
|''ALK'' fusion; activating rearrangement
|EXAMPLE: MAPK signaling
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
|EXAMPLE: Increased cell growth and proliferation
|uncontrolled cell proliferation and survival
|-
|''ROS1'' fusion; activating rearrangement
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
|cell growth and differentiation
|-
|''NTRK3'' fusion; activating rearrangement
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
|cell differentiation
|-
|-
|EXAMPLE: CDKN2A; Inactivating mutations
|''PDGFRB'' fusion; activating rearrangement
|EXAMPLE: Cell cycle regulation
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
|EXAMPLE: Unregulated cell division
|cell growth
|-
|-
|EXAMPLE: KMT2C and ARID1A; Inactivating mutations
|''RET'' fusion; activating rearrangement
|EXAMPLE: Histone modification, chromatin remodeling
|Kinase fusions, receptor tyrosine kinase/growth factor signaling
|EXAMPLE: Abnormal gene expression program
|cell growth
|}
|}
==Genetic Diagnostic Testing Methods==
==Genetic Diagnostic Testing Methods==
FISH, RT-PCR, RNA-seq
==Familial Forms==
==Familial Forms==
<br />
==Additional Information==
==Additional Information==
<br />
==Links==
==Links==
<br />
==References==
==References==